Zobrazeno 1 - 10
of 24
pro vyhledávání: '"RAKESH M. PARIKH"'
Autor:
Banshi Saboo, Rakesh M. Parikh
Publikováno v:
International Journal of Diabetes in Developing Countries
Autor:
RAKESH M. PARIKH, AMIT GUPTA, BANSHI D. SABOO, VASANTH K. CH, SANJAY AGARWAL, BRIJ M. MAKKAR, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR, ARUN NANDITHA, RAJIV R. KOVIL, SR., PURVI M. CHAWLA
Publikováno v:
Diabetes. 71
Background: Several studies have suggested that prevalence of diabetes in India is increasing, a large number of people remain undiagnosed, and overall glycemic control is poor among patients with diabetes. Although there is paucity of data from larg
Autor:
BANSHI D. SABOO, RAKESH M. PARIKH, AMIT GUPTA, VASANTH K. CH, BRIJ M. MAKKAR, SANJAY AGARWAL, PURVI M. CHAWLA, RAJIV R. KOVIL, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR, ARUN NANDITHA
Publikováno v:
Diabetes. 71
Background: Central obesity is a risk factor for cardiovascular and metabolic disorders including diabetes, hypertension and dyslipidemia. Index of central obesity (ICO) , defined as ratio of waist circumference and height, has been earlier proposed
Autor:
AMIT GUPTA, BANSHI D. SABOO, RAKESH M. PARIKH, VASANTH K. CH, SANJAY AGARWAL, BRIJ M. MAKKAR, RAJIV R. KOVIL, SR., PURVI M. CHAWLA, ARUN NANDITHA, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR
Publikováno v:
Diabetes. 71
Background: The ADA 2022 standard of care recommends routine screening for T2DM beginning from the age of 35 years, while Indian Council of Medical Research recommends to begin screening above the age of 30 years. Current study was aimed at assessing
Autor:
Rakesh M Parikh, Viswanathan Mohan
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 16, Iss 1, Pp 7-12 (2012)
The first description of patients with clustering of various metabolic abnormalities was as early as 1923 but it was more than five decades later, in 1988, that Reaven coined the term ′syndrome X′ for this entity. The last two decades have brough
Externí odkaz:
https://doaj.org/article/f3720e871bb94a0389f4e724b28bf953
Publikováno v:
Perspectives in Clinical Research, Vol 2, Iss 3, Pp 86-89 (2011)
Context: Though India has been thought to be an ideal destination for conduct of clinical drug trials, other smaller countries seem to be doing better. The pace of growth observed during 2005-2009 seems to be plateaued in 2010. Aims: There is an urge
Externí odkaz:
https://doaj.org/article/a5fee00396f84ef48fb97019fbf0ec6a
Autor:
Rakesh M Parikh
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 15, Iss 3, Pp 228-229 (2011)
Externí odkaz:
https://doaj.org/article/f5211069e2614ae090f9f65789f32fff
Publikováno v:
Metabolic Syndrome and Related Disorders. 7:525-528
The International Diabetes Federation (IDF) global definition of metabolic syndrome suggests using race- and gender-specific waist circumference (WC) cutoffs. Previously, we have hypothesized that need for gender- and race-specific cutoffs could be o
Publikováno v:
Perspectives in Clinical Research, Vol 2, Iss 2, Pp 64-66 (2011)
Perspectives in Clinical Research
Perspectives in Clinical Research
Background: Type 2 diabetes mellitus (Type 2 DM) has been recognized as the recent pandemic; India and China competing each other for the title--Diabetes Capital of the World. A number of new drugs have been recently available and has lead to a boom
Publikováno v:
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 4:10-12
Aim To study prevalence and pattern of dyslipidemia in Indian type 2 diabetic patients. Materials and methods Fasting serum lipid profiles of 788 consecutive patients with type 2 diabetes were retrieved from hospital records. Patients having one or m